Company intelligence / Profile preview
Hangzhou Ruomai Xingyi Pharmaceutical
Hangzhou, Zhejiang, Chinaruomaipharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ruomai Xingyi Pharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of innovative metabolic therapies. The company focuses on next-generation treatments for metabolic disorders, including obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Its lead programs involve multi-agonist small molecules targeting the GLP-1, GIP, and glucagon receptors. Ruomai Xingyi aims to provide oral alternatives to injectable peptide therapies, leveraging its expertise in medicinal chemistry to improve patient compliance and therapeutic outcomes.
- Therapeutic areas
- EndocrinologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hangzhou Ruomai Xingyi Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Ruomai Xingyi Pharmaceutical.